Want to see BBNX full AI Analyst Report?
BBNX Stock Chart & Stats
$12.98
--
Market closed
$12.98
--
Day’s Range― - ―
52-Week Range$8.80 - $32.71
Previous CloseN/A
VolumeN/A
Average Volume (3M)970.20K
Market Cap
$758.89M
Enterprise Value$564.47M
Total Cash (Recent Filing)$199.52M
Total Debt (Recent Filing)$6.91M
Price to Earnings (P/E)―
Beta1.14
Next Earnings
Jul 29, 2026EPS Estimate
-0.58Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.51
Shares Outstanding44,561,695
10 Day Avg. Volume701,209
30 Day Avg. Volume970,200
Financial Highlights & Ratios
PEG Ratio0.21
Price to Book (P/B)4.29
Price to Sales (P/S)12.32
P/FCF Ratio-21.97
Enterprise Value/Market Cap0.74
Enterprise Value/Revenue5.12
Enterprise Value/Gross Profit8.96
Enterprise Value/Ebitda-8.89
Forecast
1Y Price Target
$17.67Price Target Upside36.11% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
EPS Forecast (FY)-2.18
Revenue Forecast (FY)$133.70M
Bulls Say, Bears Say
Bulls Say
Revenue GrowthSustained 57% YoY top-line growth demonstrates durable commercial traction and expanding product adoption. Recurring pharmacy revenue and strong new-start conversion (≈70% migrating from MDI) indicate improving unit economics and a larger addressable base that supports multi-quarter scaling and revenue predictability.
Margin Expansion / Pharmacy MixMaterial gross margin improvement driven by pharmacy mix, manufacturing scale and lower materials cost points to more sustainable unit profitability. Management guiding higher full‑year gross margins and growing pharmacy-reimbursed starts makes recurring, higher-margin revenue a structural driver of long-term margin expansion.
Balance Sheet StrengthVery low leverage and substantial assets provide financial flexibility to fund commercialization, R&D (Mint and bihormonal) and manufacturing scale without immediate refinancing pressure. Combined with sizable cash balances noted in the quarter, this supports multi-quarter execution of strategic initiatives.
Bears Say
Cash Burn / Negative Cash FlowPersistent negative operating and free cash flow indicates the business still consumes significant cash to grow. With TTM OCF ≈ -$54.8M and Q1 cash burn ~ $25M, the company remains reliant on existing liquidity or external funding until unit economics and operating leverage meaningfully improve.
High Operating Expense IntensitySustained S&M at ~75% of revenue and accelerating OpEx growth materially pressures profitability and requires substantial scale or efficiency gains to reverse. If installed-base recurring revenue growth lags, high acquisition intensity can prolong losses and extend the time to positive operating leverage.
Regulatory Risk / FDA WarningAn outstanding FDA warning letter creates execution risk for product approvals and commercialization timelines (e.g., Mint). Ongoing remediation can divert resources, delay launches, and constrain market expansion — a structural regulatory overhang until fully resolved and closes.
Beta Bionics, Inc. News
BBNX FAQ
What was Beta Bionics, Inc.’s price range in the past 12 months?
Beta Bionics, Inc. lowest stock price was $8.80 and its highest was $32.71 in the past 12 months.
What is Beta Bionics, Inc.’s market cap?
Beta Bionics, Inc.’s market cap is $758.89M.
When is Beta Bionics, Inc.’s upcoming earnings report date?
Beta Bionics, Inc.’s upcoming earnings report date is Jul 29, 2026 which is in 16 days.
How were Beta Bionics, Inc.’s earnings last quarter?
Beta Bionics, Inc. released its earnings results on Apr 21, 2026. The company reported -$0.49 earnings per share for the quarter, beating the consensus estimate of -$0.503 by $0.013.
Is Beta Bionics, Inc. overvalued?
According to Wall Street analysts Beta Bionics, Inc.’s price is currently Undervalued.
Does Beta Bionics, Inc. pay dividends?
Beta Bionics, Inc. does not currently pay dividends.
What is Beta Bionics, Inc.’s EPS estimate?
Beta Bionics, Inc.’s EPS estimate is -0.58.
How many shares outstanding does Beta Bionics, Inc. have?
Beta Bionics, Inc. has 44,561,695 shares outstanding.
What happened to Beta Bionics, Inc.’s price movement after its last earnings report?
Beta Bionics, Inc. reported an EPS of -$0.49 in its last earnings report, beating expectations of -$0.503. Following the earnings report the stock price went down -0.57%.
Which hedge fund is a major shareholder of Beta Bionics, Inc.?
Currently, no hedge funds are holding shares in BBNX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Beta Bionics, Inc. Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$17.67 (36.11% Upside)
$17.67 (36.11% Upside)
Blogger Sentiment
Neutral
BBNX Sentiment 50%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 310.5K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $472.2K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 4.0%
Last 30 Days ▼ 4.0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
25.58%
12-Months-Change
Fundamentals
Return on Equity
-23.00%
Trailing 12-Months
Asset Growth
-9.94%
Trailing 12-Months
Company Description
Beta Bionics, Inc.
Beta Bionics, Inc. is a commercial-stage medical technology company dedicated to inventing, developing, and bringing to market solutions that improve the health and quality of life for individuals with diabetes who depend on insulin. The company's flagship product, the iLet Bionic Pancreas, is an automated insulin delivery system currently available for treating type 1 diabetes in adults and children aged six and older. In addition to its existing offering, Beta Bionics is actively developing several new innovations: a Patch Pump, designed as a tubeless insulin pump that adheres directly to the skin; the Bihormonal iLet, which integrates automated delivery of both insulin and glucagon; and an iLet system specifically adapted for individuals with insulin-dependent type 2 diabetes. To support its product pipeline, the company has forged strategic alliances, including a collaboration and licensing agreement with Xeris Pharmaceuticals, Inc. to develop and commercialize a glucagon formulation compatible with pumps. It also holds a development and commercialization agreement with Abbott Diabetes Care Inc. for an automated insulin delivery system. Established in 2015, Beta Bionics is headquartered in Irvine, California.
BBNX Company Deck
BBNX Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a largely positive commercial momentum: strong 57% YoY revenue growth, meaningful gross margin expansion (59.5% in Q1), accelerating pharmacy channel adoption, raised full-year guidance and clear pipeline progress (Mint timing reiterated and Phase IIa for bihormonal started). Offsetting risks include a seasonal sequential decline in new patient starts, materially higher operating expenses (S&M at ~75% of revenue), ongoing FDA warning letter remediation, one-time tailwinds to Q1 gross margin that may not repeat, and continued investment-driven cash burn (~$25M in Q1). On balance, the positive operating results, guidance raises, cash runway and product/pipeline execution outweigh the near-term challenges and investments.View all BBNX earnings summariesBBNX Stock 12 Month Forecast
Average Price Target
$17.67
▲(36.11% Upside)
Technical Analysis
Labcorp Holdings
―
Tandem Diabetes Care
―
Envista Holdings
―
Sana Biotechnology
―
Fortrea Holdings Inc.
―
Ownership Overview
2.82% Insiders
22.29% Mutual Funds
0.29% Other Institutional Investors
65.05% Public Companies and
Individual Investors